<DOC>
	<DOCNO>NCT02568176</DOCNO>
	<brief_summary>The primary purpose study evaluate induction potential repeat administration intranasal esketamine cytochrome P450 ( CYP ) 3A4 CYP2B6 activity healthy participant use orally administer midazolam bupropion probe , respectively evaluate pharmacokinetics esketamine single dose repeat administration .</brief_summary>
	<brief_title>Pharmacokinetic Study Intranasal Esketamine Its Effects Pharmacokinetics Orally-Administered Midazolam Bupropion Healthy Participants</brief_title>
	<detailed_description>This parallel group , single-center , repeat-dose , fixed-sequence , open-label ( people know identity intervention ) , study . The effect repeat administration intranasal esketamine pharmacokinetics midazolam bupropion evaluate Cohort 1 Cohort 2 , respectively . Participants Cohort 1 receive single oral dose midazolam morning Day 1 Day 17 . Participants Cohort 2 receive single oral dose bupropion morning Day 1 Day 19 . In Cohort 1 2 participant self-administer 5 dos intranasal esketamine 15-day period . The duration study , Screening Phase Follow-up , 51 day 54 day Cohort 1 Cohort 2 , respectively . Blood sample participant Cohort 1 collect 24 hour dose Days 1 17 ( midazolam ) 24 hour Days 2 16 ( esketamine ) ; For participant Cohort 2 , blood urine sample assessment bupropion pharmacokinetics collect 72 hour dose Day 1 Day 19 . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Bupropion</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Be man woman nonAsian origin 18 55 year age , inclusive Signed inform consent document indicate understand purpose procedure require study willing participate study A woman childbearing potential , must negative serum Î²human chorionic gonadotropin ( hCG ) pregnancy test Screening negative urine pregnancy test Day 1 treatment period . Women use contraceptive must agree use additional birth control method study 1 month receive last dose study drug A man sexually active woman childbearing potential vasectomy , must agree use adequate contraception method deem appropriate investigator ( eg , vasectomy , doublebarrier , partner use effective contraception ) donate sperm study 3 month receive last dose study drug Comfortable selfadministration intranasal medication able follow instruction provide Clinically significant abnormal value hematology , clinical chemistry ( particularly potassium magnesium level normal laboratory range ) , urinalysis Screening admission study center ( Day 1 ) deem appropriate investigator Clinically significant abnormal physical examination , vital sign , 12 lead electrocardiogram ( ECG ) Screening admission study center ( Day 1 ) deem appropriate investigator Use prescription nonprescription medication ( include vitamin herbal supplement ) , except paracetamol , contraceptive , hormonal replacement therapy , within 14 day first dose study drug schedule completion study Has use nasal tobacco powder ( `` snuff '' ) regularly within past year . Has nasal pierce</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Esketamine</keyword>
	<keyword>JNJ-54135419</keyword>
	<keyword>Midazolam</keyword>
	<keyword>Bupropion</keyword>
</DOC>